Post-COVID-19 Myoclonus-Ataxia Syndrome-Is there Really a Need for Intravenous Immunoglobulin Treatment in all Cases?
- PMID: 37070049
- PMCID: PMC10105119
- DOI: 10.1002/mdc3.13695
Post-COVID-19 Myoclonus-Ataxia Syndrome-Is there Really a Need for Intravenous Immunoglobulin Treatment in all Cases?
Keywords: COVID‐19; SARS CoV‐2; ataxia; myoclonus.
References
-
- Sawczyńska K, Wężyk K, Bosak M, et al. Acute‐onset chorea and confusional state in 77‐year‐old COVID‐19 patient: a case report. Neurol Neurochir Pol 2022;56(1):106–110. - PubMed
-
- Hirschfeld AS. Autoimmune mediated hyperkinetic movement disorders in SARS‐CoV‐2 infection—a systematic review. Neurol Neurochir Pol 2021;55(6):549–558. - PubMed
-
- Schneider SA, Hennig A, Martino D. Relationship between COVID‐19 and movement disorders: a narrative review. Eur J Neurol 2022;29(4):1243–1253. - PubMed
-
- Przytuła F, Błądek S, Sławek J. Two COVID‐19‐related video‐accompanied cases of severe ataxia‐myoclonus syndrome. Neurol Neurochir Pol 2021;55(3):310–313. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous
